Previous close | 8.52 |
Open | 8.80 |
Bid | 6.14 x 200 |
Ask | 7.98 x 100 |
Day's range | 7.72 - 8.80 |
52-week range | 7.11 - 15.49 |
Volume | |
Avg. volume | 33,333 |
Market cap | 188.928M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.35 |
Earnings date | 07 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 12.61 |
TORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the first quarter ended March 31, 2024 and provided full-year 2024 revenue guidance. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in acc
— So far this year alone, 25 TULSA-related scientific research presentations have been delivered at major medical meetings around the world — — Of those, eight (8) presentations were from leading urologists at AUA 2024 — — Clinical evidence continues to highlight TULSA’s ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH — TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-s
Key Insights Given the large stake in the stock by institutions, Profound Medical's stock price might be vulnerable to...